Abbott Laboratories' medical device business is executing well, with double-digit growth in structural heart and diabetes.

The decision to allow a new trial could have  implications for both the companies and families with babies born prematurely.

Shares of Abbott Laboratories ABT slid 3.42% to $132.66 Tuesday, on what proved to be an all-around rough trading session for ...

Infant formula makers Abbott and Reckitt saw their stocks decline Friday after a judge ruled plaintiffs could pursue a new ...

Abbott Laboratories is undervalued with strong growth in diabetes care and weight-loss markets. Discover why ABT stock is a ...

In the last year, many Abbott Laboratories ( NYSE:ABT ) insiders sold a substantial stake in the company which may ...

ABT's shares rise on the back of its diversified business portfolio. However, the unfavorable macroeconomic scenario is concerning.

This was the stock's second consecutive day of losses.

Abbott Laboratories and Reckitt Benckiser Group Plc shares fell as a judge ordered a new trial after rejecting a verdict that ...

Back in October, a jury found North Chicago-based Abbott and Reckitt’s formula subsidiary Mead Johnson not responsible for a ...

Shares of Abbott Laboratories and Reckitt Benckiser fell Friday after a judge ruled a new trial could be heard involving a case on their infant formula products that had already seen a ruling in their ...

We recently published a list of 10 Best Healthcare Stocks For Long-Term Investment. In this article, we are going to take a ...